Identification of TMEM106B amyloid fibrils provides an updated view of TMEM106B biology in health and disease

• Published in: Acta neuropathologica 2022-11, Vol.144 (5), p.807-819
• Main Authors: Perneel, Jolien, Rademakers, Rosa
• Format: Article
• Language: English
• Subjects: Aging; Amyloid - metabolism; Disease; Fibrils; Frontotemporal dementia; Frontotemporal Lobar Degeneration - genetics; Genetic aspects; Health risk assessment; Humans; Intercellular Signaling Peptides and Proteins - metabolism; Lysosomes; Lysosomes - metabolism; Medicine; Medicine & Public Health; Membrane Proteins - genetics; Membrane Proteins - metabolism; Nerve Tissue Proteins - genetics; Nerve Tissue Proteins - metabolism; Nervous system diseases; Neurodegeneration; Neurodegenerative diseases; Neurosciences; Pathology; Protein folding; Proteins; Review; Risk factors
• ISSN: 0001-6322; 1432-0533; 1432-0533
• DOI: 10.1007/s00401-022-02486-5

Since the initial identification of TMEM106B as a risk factor for frontotemporal lobar degeneration (FTLD), multiple genetic studies have found TMEM106B variants to modulate disease risk in a variety of brain disorders and healthy aging. Neurodegenerative disorders are typically characterized by inclusions of misfolded proteins and since lysosomes are an important site for cellular debris clearance, lysosomal dysfunction has been closely linked to neurodegeneration. Consequently, many causal mutations or genetic risk variants implicated in neurodegenerative diseases encode proteins involved in endosomal–lysosomal function. As an integral lysosomal transmembrane protein, TMEM106B regulates several aspects of lysosomal function and multiple studies have shown that proper TMEM106B protein levels are crucial for maintaining lysosomal health. Yet, the precise function of TMEM106B at the lysosomal membrane is undetermined and it remains unclear how TMEM106B modulates disease risk. Unexpectedly, several independent groups recently showed that the C-terminal domain (AA120-254) of TMEM106B forms amyloid fibrils in the brain of patients with a diverse set of neurodegenerative conditions. The recognition that TMEM106B can form amyloid fibrils and is present across neurodegenerative diseases sheds new light on TMEM106B as a central player in neurodegeneration and brain health, but also raises important new questions. In this review, we summarize current knowledge and place a decade’s worth of TMEM106B research into an exciting new perspective.